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Background
An 8-week, multicentre, open-label, dose titration study
of Quetiapine (Seroquel®) in patients with Schizophrenia
was carried out with the objectives to (a) record the titra-
tion scheme and maximum achieved dose of Quetiapine
for each patient and (b) assess the clinical efficacy and tol-
erability of Quetiapine as monotherapy.
Material and Methods
The study took place at 45 primary health care and hospi-
tal study sites. Patients diagnosed with schizophrenia of
mild to moderate severity, hospitalized or outpatients,
newly diagnosed or in acute exacerbation of chronic or
subchronic schizophrenia were included in the study. All
patients were required to score (a) at least 45 on the 18-
item BPRS, (b) at least 4 (moderate) on two or more of
BPRS items and (c) at least 3 on the CGI Severity of Illness
item. Patients should be titrated with the assistance of
"the Quetiapine titration pack" and reach the dose of 400
mg by day 5. During follow up the optimum dose for each
patient should be reached in order to achieve symptoms'
control. Psychopathology was assessed at baseline and at
each of the six scheduled visits with the assistance of the
BPRS, PANSS, CGI, and SAS scales. An overall assessment
scale was also included, asking doctors to rate patients'
progress as high, moderate or low improvement. Investi-
gators were allowed to evaluate patients on all or selected
rating scales. They were also allowed to prescribe concom-
itant medication (lorazepam, chloral hydrate, zolpidem).
Before study enrollment patients provided written or wit-
nessed verbal informed consent. In an intention to treat
analysis, Chi-Square, Fischer's Exact Test and Analysis of
Variance (ANOVA) were used as appropriate.
Results
419 patients were eligible for statistical evaluation. Mean
age was 37+ 11.5 years. 236 (56.32%) patients were male
and 183 (43.68%) female. 68 (16.23%) patients were
newly diagnosed and 351 (83.77%) were in acute exacer-
bation of chronic or subchronic schizophrenia.
Evaluated patients completed the dose titration period as
follows: Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day
4: 300 mg, Days 5–8: 400 mg, Day 9: 600 mg. At day 56
(end of study period) in 117 patients (27.92%) the dose
was maintained at 600 mg, in 239 patients (57.04%) the
dose increased to 800 mg and in 63 patients (15.04%) the
dose reached 1200 mg/day. Mean Quetiapine dose was
690 mg at day 56. Previous medication wash out was per-
formed by dose decrease from 100% (day 1) to 50% (day
4) and finally 0% (day 8).
Regarding treatment efficacy, 241 (57.51%) patients were
evaluated by overall assessment, 70 (16.71%) patients
were evaluated by BPRS and 108 (25.78%) patients were
evaluated by CGI. Based on psychopathology therapy
evaluation 318 (75.89%) patients expressed high
improvement score during overall treatment assessment,
83 (19.81%) patients expressed medium improvement
score and 18 (4.3%) patients expressed low improvement
score (p = 0.000). 28 patients (6.68%) recorded the fol-
lowing AEs: sedation (11), mild BP decrease (9), somno-
lence (8). No other AEs were reported during the study
period.
Discussion
1) Dose titration of Quetiapine started at day 1 with 50
mg and reached 600 mg by day 9. Thereafter dose was
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individually adjusted and reached a maximum of 1200
mg by day 56. Overall the mean dose for the study popu-
lation at day 56 was 690 mg of Quetiapine. 2) Overall
Quetiapine proved to be effective in improving patients'
symptoms as 75.89% of patients showed high improve-
ment according to the overall psychopathology assess-
ment score, 19.81% showed moderate improvement,
whereas only 4.3% showed low improvement. 3) Newly
diagnosed patients were maintained at lower dose than
already diagnosed patients. 4) The rates of recorded AEs
were extremely low (6.68%) and not dose dependent.Page 2 of 2
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